Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.
about
Authors' Reply to Pires et al.: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes".Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis.Biosimilar switching - current state of knowledgeNon-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar AgentNon-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
P2860
Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Subjective Complaints as the M ...... imab to Biosimilar Infliximab.
@en
Subjective Complaints as the M ...... imab to Biosimilar Infliximab.
@nl
type
label
Subjective Complaints as the M ...... imab to Biosimilar Infliximab.
@en
Subjective Complaints as the M ...... imab to Biosimilar Infliximab.
@nl
prefLabel
Subjective Complaints as the M ...... imab to Biosimilar Infliximab.
@en
Subjective Complaints as the M ...... imab to Biosimilar Infliximab.
@nl
P2093
P2860
P356
P1476
Subjective Complaints as the M ...... imab to Biosimilar Infliximab.
@en
P2093
Alphons J L de Jong
Bart J F van den Bemt
Frank H J van den Hoogen
Iris L van Ingen
Lieke Tweehuysen
Willemijn H van der Laan
P2860
P356
10.1002/ART.40324
P577
2017-10-18T00:00:00Z